OMNIOX INC
Oxygen delivery biologic therapies using H-NOX platform technology
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Latest Form D
- $24.1M, Mar 2026
- Total capital
- $50.6M
- Federal grants
- $11.2M
- 12 awards · 2015–2025
- Rank in peer group#294 of 514
- Private capital raised
- $39.4M
- 5 Form D · last Mar 2026
- 7 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 17 pending · first 2019
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$24.1M
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$991K
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$996K
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$1.0M
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$1.0M
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$232K
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$682K
- Private capital raisedForm D · SEC · 4th filing$4.7M
- Private capital raisedForm D · SEC · 3rd filing$6.6M
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$1M
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$1M
- Federal grantHealth and Human S · Phase II · Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass$298K
- Federal grantHealth and Human S · Phase II · Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier$1.2M
- Federal grantHealth and Human S · Phase II · Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide Neutral Oxygen Carrier$2.3M
- Federal grantHealth and Human S · Phase II · Reducing Brain Injury After Focal Ischemia Using a Nitric Oxide-Neutral Oxygen Carrier$1.1M
- Federal grantHealth and Human S · Phase I · Chemosensitizing Hypoxic Multiple Myeloma With Tunable, Long-Lived Oxygen Carriers$280K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#71 · top 14%
- Linked publications#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stephen CaryResearcherExecutive Officer, DirectorLinked by 1 patent · $3.7M in grants as PI
- Jonathan WingerResearcherExecutive Officer, DirectorLinked by $1.0M in grants as PI
- Ajit ShahDirectorNamed in SEC Form D filings
- Jeffrey S. SambergDirectorNamed in SEC Form D filings
- Jeff SambergDirectorNamed in SEC Form D filings
- John WesleyDirectorNamed in SEC Form D filings
Show all 8 people
- Laurence S. MartonDirectorNamed in SEC Form D filings
- Mitchell S. MutzDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 22- PendingModulation Of Tumor Immunity By Protein-Mediated O2 DeliveryUSPTOApplication 19188574
- GrantedModulation Of Tumor Immunity By Protein-mediated O2 DeliveryUSPTOUS 12,285,463
- PendingH-nox Proteins For Organ PreservationUSPTOApplication 18684586
Show all 22 patent records
- Modulation Of Tumor Immunity By Protein-Mediated O2 DeliveryMay 28, 2026 · Application 19188574Pending
- Modulation Of Tumor Immunity By Protein-mediated O2 DeliveryApr 29, 2025 · US 12,285,463Granted
- H-nox Proteins For Organ PreservationNov 14, 2024 · Application 18684586Pending
- Polymeric Forms Of H-nox ProteinsMay 21, 2024 · US 11,987,614Granted
- Modulation Of Hypoxia Associated With StrokeJan 25, 2024 · Application 18308203Pending
- Polymeric Forms Of H-nox ProteinsSep 14, 2021 · US 11,117,952Granted
- Modulation Of Hypoxia Associated With StrokeApr 29, 2021 · Application 17133180Pending
- Polymeric Forms Of H-nox ProteinsSep 8, 2020 · US 10,766,947Granted
- Modulation Hypoxia Associated With StrokeSep 3, 2020 · Application 15998557Pending
- Polymeric Forms Of H-nox ProteinsAug 20, 2019 · US 10,385,116Granted
- Modulation Of Tumor Immunity By Protein-mediated O2 DeliveryAug 30, 2018 · Application 15558957Pending
- Biomarkers For H-nox Delivery Of OxygenOct 1, 2015 · Application 14530569Pending
- Modulation Hypoxia Associated With StrockeApplication PCTUS2017018233Pending
- Modulation Of Tumor Immunity By Protein-mediated 02 DeliveryApplication PCTUS2016022981Pending
- Modulation Of Hypoxia Associated With Injury To An Organ By Protein O2 CarriersApplication 62296009Pending
- Modulation Of Tumor Immunity By Protein-mediated 02 DeliveryApplication 62134523Pending
- Biomarkers For H-nox Delivery Of OxygenApplication 61907983Pending
- Biomarkers For H-nox Delivery Of OxygenApplication 61898395Pending
- Treating Cardiovascular And Pulmonary ConditionsApplication PCTUS2019046519Pending
- Polymeric Forms Of H-nox ProteinsApplication PCTUS2013020602Pending
- H-nox Proteins For Organ PreservationApplication 63234454Pending
- H-nox Proteins For Organ PreservationApplication PCTUS2022075179Pending
Recent research by its founders
- Abstract 1676: HA-00495: A development candidate ADC featuring a novel protein translation inhibitor payload with broad efficacy and a favorable non human primate safety profile20260 cites
- Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein20243 cites
- Assessment of tumor hypoxia in spontaneous canine tumors after treatment with OMX, a novel H-NOX oxygen carrier, with [18F]FMISO PET/CT20242 cites
Related companies, and why
- Cardior PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Glycobac, LLCSimilar federal contract value in Biotech · null in contracts
- ZENOPHARM, LLCSimilar federal contract value in Biotech · null in contracts
- IMMUSOFT CORPSimilar federal contract value in Biotech · null in contracts
- DARE BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- Ventus TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .